Table 1. Demographic and Treatment Characteristics of Survivors Exposed to CNS-Directed Therapy (N= 1304).
| Mean | SD | |
|---|---|---|
| Age at Evaluation (years) | 31.6 | 7.9 |
| Age at Diagnosis (years) | 7.5 | 5.0 |
|
|
||
| N | %* | |
|
|
||
| Age at Evaluation (years) | ||
| 18-30 | 637 | 48.8 |
| 31-40 | 472 | 36.2 |
| >40 | 195 | 15.0 |
| Age at Diagnosis (years) | ||
| 0-4 | 486 | 37.3 |
| 5-9 | 368 | 28.2 |
| 10-14 | 306 | 23.5 |
| ≥15 | 144 | 11.0 |
| Time since Diagnosis (years) | ||
| 10-19 | 439 | 33.7 |
| ≥20 | 865 | 66.3 |
| Gender | ||
| Male | 654 | 50.2 |
| Female | 650 | 49.8 |
| Ethnicity | ||
| Caucasian | 1145 | 87.8 |
| Other | 159 | 12.2 |
| Education | ||
| ≤Some college | 790 | 62.5 |
| ≥College | 474 | 37.5 |
| Marital Status | ||
| Single, never married | 488 | 38.6 |
| Married, living as married | 601 | 47.6 |
| Divorced, no longer living as married | 175 | 13.8 |
| Living Arrangement** | ||
| Dependent | 390 | 29.9 |
| Independent | 914 | 70.1 |
| Household Income | ||
| <$40,000 | 520 | 47.2 |
| ≥$40,000 | 582 | 52.8 |
| Health Insurance | ||
| Yes | 996 | 76.7 |
| No | 302 | 23.3 |
| Dental Insurance | ||
| Yes | 696 | 55.8 |
| No | 552 | 44.2 |
| Diagnosis+ | ||
| Leukemia | 872 | 66.9 |
| Lymphoma | 129 | 9.9 |
| CNS Tumor | 142 | 10.9 |
| Embryonal | 26 | 2.0 |
| Bone and Soft Tissue Sarcoma | 111 | 8.5 |
| Other | 24 | 1.8 |
| Radiation+ | ||
| Chest | 212 | 16.3 |
| Cranial (CRT) | 674 | 51.7 |
| Chemotherapy+ | ||
| Anthracyclines | 825 | 63.3 |
| Alkylating Agents | 860 | 66.0 |
| Antimetabolites | 990 | 75.9 |
| Anti-Tumor Agents | 67 | 5.1 |
| Corticosteriods | 952 | 73.0 |
| Platinum | 122 | 9.4 |
| CNS Directed Therapy+ | ||
| HD/IV/IT/IO MTX‡ | 1036 | 79.5 |
| HD Ara-C‡‡ | 105 | 8.1 |
| HD/IV/IT/IO MTX and HD Cytarabine | 1057 | 81.1 |
| HD/IV/IT/IO MTX and CRT | 1196 | 91.2 |
| HD Ara-C and CRT | 725 | 55.6 |
| HD/IV/IT/IO MTX, HD Ara-C and CRT | 1199 | 92.0 |
*
Percentages based on participants with available data
**
independent living (living alone, with a spouse/roommate or as a caretaker); dependent living (living with parents/family)
+
variable not included in multivariable models
‡
high dose/intravenous/intrathecal/intra-ommaya methotrexate
‡‡
high dose cytarabine